Der Urologe

, Volume 52, Issue 5, pp 691–702 | Cite as

Die Versorgungssituation von Patienten mit interstitieller Zystitis in Deutschland

Ergebnisse einer Umfrage unter 270 Betroffenen
Originalien

Zusammenfassung

Hintergrund

Mittels eines umfangreichen Fragebogens wurde die Versorgungssituation von 270 an interstitieller Zystitis (IC, „bladder pain syndrome“) erkrankten Patienten in Deutschland erfasst. Trotz umfangreicher Literatur zur IC (62.000 Literaturstellen in PubMed) ist über den Versorgungsalltag und die Qualität der Patientenversorgung fast nichts bekannt.

Ergebnisse

Die Patienten sind zu 94 % weiblich, zu 6 % männlich. Das Durchschnittsalter der Frauen beträgt 53,5 Jahre, das der Männer 67,0 Jahre. Die Patienten fühlen sich zu 47,77 % über ihre Erkrankung gut bis sehr gut informiert – 75 % von ihnen wünschen sich aber weitergehende Informationen. Als Informationsquelle dient in vielen Fällen das Internet. Durch die sozialen Netzwerke wird der Informationsaustausch unter den Patienten voraussichtlich zunehmen. Die Diagnose IC wurde am häufigsten (62,22 %) durch Biopsie/histologische Untersuchung gestellt. Es folgen Urodynamik, Kaliumtest, Hydrodistension und Zystoskopie. Die durchschnittliche Diagnosedauer betrug 9 Jahre. 46,67 % der Patienten suchten über 20-mal einen Arzt auf, ehe die Diagnose gestellt wurde; 51,84 % der Patienten müssen pro Tag > 14-mal Wasser lassen. Pollakisurie, Nykturie und Schmerzen stehen an der Spitze der beklagten Beschwerden. Ein Viertel der Patienten klagt über eine Dranginkontinenz. Von oralen Medikamenten werden Schmerzmittel am häufigsten eingenommen (61,7 %), gefolgt von Pentosanpolysulfat, Antidepressiva, Antiepileptika, Krampflösern und Mitteln gegen Harndrang. In der Patienteneinschätzung des Behandlungserfolgs (sehr gut und gut geholfen) der oralen Medikamente führen Pentosanpolysulfat, Schmerzmittel, Antidepressiva und Antiepileptika. Zur Instillation in die Harnblase werden hauptsächlich Medikamente, die die Glycosaminauskleidung der Blase wieder herstellen, angewendet: Hyaluronsäure, Chondroitinsulfat, die Kombination von beiden und Pentosanpolysulfat. Bei der Patienteneinschätzung des Behandlungserfolgs (sehr gut und gut geholfen) der Instillationstherapie lautet die Reihung: Chondroitinsulfat (62,69 %), Hyaluronsäure (55,77 %), Kombination von beiden (53,66 %) und Pentosanpolysulfat (46,30 %). Überraschend häufig (bei 119 Patienten) wurde das EMDA-Verfahren („electromotive drug administration“) mit Gleichstromanwendung zur Medikamenteneinbringung in die Blasenwand genannt. Der Erfolg (sehr gut und gut geholfen) lag in der Selbsteinschätzung mit 61,34 % an der Spitze der intravesikalen Verfahren.

Schlussfolgerung

Im Vergleich aller medikamentöser Verfahren in der Selbsteinschätzung der Patienten liegt die Instillation von Medikamenten in die Harnblase mit 53,53 % sehr gut geholfen und spürbar geholfen bei 368 Nennungen vorn, gefolgt von speziellen invasiven Verfahren mit 50,56 % (n = 271), alternativen Therapien mit 41,11 % (n = 287) und oraler Medikation mit 39,75 % (n = 1024). Hyaluronsäure- und Chondroitinsulfatpräparate, die Kombination von beiden und Pentosanpolysulfat (oral und intravesikal) werden von den gesetzlichen Krankenkassen nicht erstattet. Über 40 % der damit Behandelten brachen daher aus Kostengründen die Therapie ab.

Schlüsselwörter

Versorgungsforschung Becken-Schmerz-Syndrom Alltagsversorgung Intravesikale Verfahren Harnblase 

The care situation of patients with interstitial cystitis in Germany

Results of a survey of 270 patients

Abstract

Background

Using a comprehensive questionnaire the care situation of 270 patients with interstitial cystitis (IC) and bladder pain syndrome in Germany was recorded. Despite comprehensive literature on IC (62,000 citations in PubMed) almost nothing is known of the everyday care and quality of patient care in Germany.

Results

In total 94 % of the patients were women and 6 % men, the average age of women was 53.5 years and that of men 67 years and 47.77 % of the patients felt that they were well or very well informed about the disease whereby the internet was the source of information in many cases. The exchange of information among patients will increase further through social networks. The diagnosis of IC was made most frequently (62.22 %) by biopsy and histological examination followed by urodynamics, potassium test, hydrodistension and cystoscopy. The average duration of the diagnosis was 9 years, 46.67 % of the patients consulted a doctor more than 20 times before the diagnosis was made and 51.84 % had to pass water more than 14 times per day. Frequency, nocturia and pain were the leading symptoms and 25 % of the patients complained of urge incontinence. Among oral medications, analgesics were taken most frequently (61.7 %) followed by pentosan polysulphate, antidepressants, antiepileptic drugs, antispasmodics and remedies for urinary urgency. In the self-assessment of the success of treatment with oral medications (helped very well and well), pentosan polysulphate, analgesics, antidepressants and antiepileptic drugs were considered to be the best. Medications that restore the glucosamine lining of the bladder were used predominantly for instillation into the bladder included hyaluronic acid, chondroitin sulphate and a combination of both and pentosan polysulphate. In the self-assessment of the success of treatment with instillation therapy (helped very well or well) the order was: chondroitin sulphate (62.69 %), hyaluronic acid (55.77 %), a combination of both (53.66 %) and pentosan polysulphate (46.30 %). The electromotive drug administration (EMDA) procedure with the use of direct current to introduce medications into the bladder wall was mentioned surprisingly often, namely, in 119 patients. In the self-assessment success (helped very well or well) was considered the best for intravesical procedures with 61.34 %.

Conclusions

Compared with all drug procedures instillation of medications into the bladder was mentioned 368 times and was assessed by the patients as having helped very well and noticeably by 53.53 %, followed by special invasive procedures at 50.56 %/271 mentions, alternative therapies at 41.11 %/287 mentions and oral medication at 39.75 %/1,024 mentions. Hyaluronic acid and chondroitin sulphate products, the combination of both and pentosan polysulphate (oral and intravesical) are not reimbursed by the statutory health insurance. Over 40 % of patients treated with these therefore discontinued the treatment for reasons of cost.

Keywords

Healthcare research Bladder pain syndrome Routine care Intravesical procedures Bladder 

Literatur

  1. 1.
    Andersen AV, Granlund P, Schultz A et al (2012) Long-term experience with surgical treatment of selected patients with bladder pain syndrome/interstitial cystitis. Scand J Urol Nephrol 46(4):284–289PubMedCrossRefGoogle Scholar
  2. 2.
    Anderson RU, Orenberg EK, Morey A et al (2009) Stress induced hypothalamus-pituitary-adrenal axis responses and disturbances in psychological profiles in men with chronic prostatitis/chronic pelvic pain syndrome. J Urol 182(5):2319–2324PubMedCrossRefGoogle Scholar
  3. 3.
    Anger JT, Zabihi N, Clemens JQ, Payne CK et al (2011) Treatment choice, duration, and cost in patients with interstitial cystitis and painfull bladder syndrome. Int Urogynecol J 22(4):395–400PubMedCrossRefGoogle Scholar
  4. 4.
    Bassaly R, Downes K, Hart S (2011) Dietary consumption triggers in interstitial cystitis/bladder pain syndrome patients. Female Pelvic Med Reconstr Surg 17(1):36–39PubMedCrossRefGoogle Scholar
  5. 5.
    Berry SH, Elliot MN, Suttorp M et al (2011) Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol 186(2):540–544PubMedCrossRefGoogle Scholar
  6. 6.
    Blalock EM, Korrect GS, Stromberg AJ, Erickson DR (2012) Gene expression analysis of urine sediment: evaluation for potential noninvasive markers of interstitial cystitis/bladder pain syndrome. J Urol 187(2):725–732PubMedCrossRefGoogle Scholar
  7. 7.
    BMBF (2010) Bildung in Deutschland 2010. Ein indikatorengestützter Bericht mit einer Analyse zu Perspektiven des Bildungswesens im demographischen Wandel. Kultusministerkonferenz, Bundesministerium für Bildung u. Forschung. Bertelsmann, München, DNB-Katalog der Deutschen Nationalbibliothek (http://dnb.ddb.de), ISBN 978–3-7639-1992-5Google Scholar
  8. 8.
    Bogart LM, Suttorp MJ, Elliot MN et al (2011) Prevalence and correlates of sexual dysfunction among women with bladder pain syndrome/interstitial cystitis. Urology 77(3):576–580PubMedCrossRefGoogle Scholar
  9. 9.
    Butrick CW (2012) Interstitial cystitis/bladder pain syndrome: management of the pain disorder: a urogynecology perspective. Urol Clin North Am 39(3):377–387PubMedCrossRefGoogle Scholar
  10. 10.
    Chelimsky G, Heller E, Buffington CA et al (2012) Co-morbidities of interstitial cystitis. Front Neuroscience 6:114Google Scholar
  11. 11.
    Cheng C, Rosamilia A, Healey M (2012) Diagnosis of interstitial cystitis/bladder pain syndrome in women with chronic pelvic pain: a prospective observational study. Int Urogyn J 23(10):1361–1366CrossRefGoogle Scholar
  12. 12.
    Clemens JQ, Meenan RT, Rosetti MC et al (2008) Costs of interstitial cystitis in a managed care population. Urology 71(5):776–781PubMedCrossRefGoogle Scholar
  13. 13.
    Clemens JQ, Bogart LM, Liu K et al (2011) Perceptions of „urgency“ in women with interstitial cystitis/bladder pain syndrome or overactive bladder. Neurourol Urodyn 30(3):402–405PubMedCrossRefGoogle Scholar
  14. 14.
    Close CE, Carr MC, Burns MW et al (1996) Interstitial cystitis in children. J Urol 156(2):860–862PubMedCrossRefGoogle Scholar
  15. 15.
    Corcoran AT, Yoshimura N, Tyagi V et al (2012) Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens. World J Urol 31(1):241–246PubMedCrossRefGoogle Scholar
  16. 16.
    Daha LK, Riedl CR, Lazar D et al (2005) Do cystometric findings predict the results of intravesical hyaluronic acid in women with interstitial cystitis? Eur Urol 47(3):393–397PubMedCrossRefGoogle Scholar
  17. 17.
    Engelhardt PF, Morakis N, Daha LK et al (2011) Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis. Int Urogynecol J 22(4):401–405PubMedCrossRefGoogle Scholar
  18. 18.
    Evans RJ, Moldwin RM, Cossons N et al (2011) Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol 185(5):1716–1721PubMedCrossRefGoogle Scholar
  19. 19.
    Fall M, Baranowski AP, Eleneil S et al (2010) EAU guidelines on chronic pelvic pain. Eur Urol 57:35–48PubMedCrossRefGoogle Scholar
  20. 20.
    Farmer M, Chanda ML, Parks EL et al (2011) Brain functional and anatomical changes in chronic prostatits/chronic pelvic pain syndrome. J Urol 186:117–124PubMedCrossRefGoogle Scholar
  21. 21.
    Friedlander JI, Shorter B, Moldwin RM (2012) Diet and its role in interstitial cystitis/bladder pain syndrome (IC/BPS) and comorbid conditions. BJU Int 109(11):1584–1591PubMedCrossRefGoogle Scholar
  22. 22.
    Gafni-Kane A, Botros SM, Du H et al (2013) Measuring the success of combined intravesical dimethyl sulfoxide and triamcinolone for treatment of bladder pain syndrome/interstitial cystitis. Int Urogynecol J 24(2):303–311PubMedCrossRefGoogle Scholar
  23. 23.
    Gardella B, Porru D, Nappi RE et al (2011) Interstitial cystitis is associated with vulvodynia and sexual dysfunction – a case-control study. J Sex Med 8(6):1726–1734PubMedCrossRefGoogle Scholar
  24. 24.
    Giannantoni A, Cagini R, Del Zingaro M et al (2010) Botulinum A toxin intravesical injections for painful bladder syndrome: impact upon pain, psychological functioning and Quality of Life. Curr Drug Deliv 7(5):442–446PubMedCrossRefGoogle Scholar
  25. 25.
    Ginting JV, Tripp DA, Nickel JC et al (2011) Spousal support decreases the negative impact of pain on mental quality of life in women with interstitial cystitis/painful bladder syndrome. BJU Int 108(5):713–717PubMedGoogle Scholar
  26. 26.
    Glaeske G, Augustin M, Abholz H et al (2009) Epidemiologische Methoden für die Versorgungsforschung. Gesundheitswesen 71(10):685–693PubMedCrossRefGoogle Scholar
  27. 27.
    Gottsch HP, Miller JL, Yang CC, Berger RE (2011) A pilot study of botulinum toxin for interstitial cystitis/painful bladder syndrome. Neurourol Urodyn 30(1):93–96PubMedCrossRefGoogle Scholar
  28. 28.
    Ham BK, Kim JH, Oh MM et al (2012) Effects of combination treatment of intravesical resiniferatoxin instillation and hydrodistention in patients with refractory painful bladder syndrome/interstitial cystitis: a pilot study. Int Neurourol J 16(1):41–46PubMedCrossRefGoogle Scholar
  29. 29.
    Hanley RS, Stoffel JT, Zagha RM et al (2009) Multimodal therapy for painful bladder syndrome/interstitial cystitis: pilot study combining behavioral, pharmacologic, and endoscopic therapies. Int Braz J Urol 35(4):467–474PubMedCrossRefGoogle Scholar
  30. 30.
    Hanno PM, Burks DA, Clemens JQ et al (2011) AUA Guideline for the diagnosis and treatment of interstitial Cystitis/bladder pain syndrome. J Urol 185(6):2162–2170PubMedCrossRefGoogle Scholar
  31. 31.
    Hepner KA, Watkins KE, Elliot MN et al (2012) Suicidal ideation among patients with bladder pain syndrome/interstitial cystitis. Urology 80(2):280–285PubMedCrossRefGoogle Scholar
  32. 32.
    Hill JR, Isom-Batz G, Panagopoulos G et al (2008) Patient perceived outcomes of treatments used for interstitial cystitis. Urology 71(1):62–66PubMedCrossRefGoogle Scholar
  33. 33.
    Hoffmann F, Huber J (2011) Die Urologie braucht Versorgungsforschung. Urologe 50:678–684PubMedCrossRefGoogle Scholar
  34. 34.
    Homma Y, Ueda T, Ito T et al (2009) Japanese guideline for diagnosis and treatment of interstitial cystitis. J Urol 16:4–16Google Scholar
  35. 35.
    Homma Y, Ueda T, Tomoe H et al (2009) Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome. J Urol 16:597–615Google Scholar
  36. 36.
    Huber J, Peters D, Kessler A et al (2010) Selbsthilfe im Onlineforum bei lokal begrenztem Prostatakarzinom: Qualitative Analyse der Entscheidungsfindung. Urologe 49:1377–1384PubMedCrossRefGoogle Scholar
  37. 37.
    Humphrey L, Arbuckle R, Moldwin R et al (2012) The bladder pain/interstitial cystitis symptom score: development, validation, and identification of a cut score. Eur Urol 61(2):271–279PubMedCrossRefGoogle Scholar
  38. 38.
    Hung MJ, Chen YT, Shen PS et al (2012) Risk factors that affect the treatment of interstitial cystitis using intravesical therapy with a dimethyl sulfoxide cocktail. Int Urogynecol J 23(11):1533–1539PubMedCrossRefGoogle Scholar
  39. 39.
    Jocham B (2012) Lebensbilder von Frauen mit IC; Emotionale u. kognitive Elemente bei der Entstehung, Aufrechterhaltung u. Reduktion chronischer Schmerzen am Beispie IC/BPS. Dt. Nationalbibliographie der Deutschen Nationalbibliothek, Dissertation, http://dnb.d-nb.deGoogle Scholar
  40. 40.
    Kaneko G, Nishimoto K, Ito Y, Uchida A (2012) The combination therapy of prednisolone and tacrolimus for severe painful bladder syndrome/interstitial cystitis. Can Urol Assoc J 6(2):46–49CrossRefGoogle Scholar
  41. 41.
    Kang JH, Keller JJ, Chen YK, Lin HC (2012) Reflux esophagitis increased the risk of bladder pain syndrome/interstitial cystitis: A 3-year follow-up study. Neurourol Urodyn 21(11):1139–1143Google Scholar
  42. 42.
    Katz L, Tripp DA, Nickel JC et al (2012) Disability in women suffering from interstitial cystitis/bladder pain syndrome. BJU Int 111(1):114–121PubMedCrossRefGoogle Scholar
  43. 43.
    Keay S, Leitzell S, Ochrzcin A et al (2012) A mouse model for interstitial cystitis/painful bladder pain syndrome based on APF inhibition of bladder epithelial repair: a pilot study. BMC Urol 12(1):17PubMedCrossRefGoogle Scholar
  44. 44.
    Keller J, Chiou HY, Lin HC (2012) Increased risk of bladder cancer following diagnosis with bladder pain syndrome/interstitial cystitis. Neurourol Urodyn 32(1):58–62PubMedCrossRefGoogle Scholar
  45. 45.
    Konkle KS, Berry SH, Elliott MN et al (2012) Comparison of an interstitial cystits/bladder pain Syndrome clinical cohort with symptomatic community women from the RAND Interstitial Cystitis epidemiology study. J Urol 187(2):508–512PubMedCrossRefGoogle Scholar
  46. 46.
    Koziol JA, Clark DC, Gittes RF, Tan EM (1993) The natural history of interstitial cystitis: a survey of 374 patients. J Urol 149(3):465–469PubMedGoogle Scholar
  47. 47.
    Kummervold PE, Chronaki CE, Lausen B et al (2008) e-Health trends in Europe 2005–2007: a population based survey. J Med Internet Res 10:42CrossRefGoogle Scholar
  48. 48.
    Kuo YC, Kuo HC (2012) Potential factors that can be used to differentiate between interstitial cystitis/painful bladder syndrome and bladder oversenitivity in women. Int J Clin Pract 66(2):146–151PubMedCrossRefGoogle Scholar
  49. 49.
    Lai MC, Kuo YC, Kuo HC (2012) Intravesical hyaluronic acid for interstitial cystitis/painful bladder syndrome: a comparative randomized assessment of different regimens. Int J Urol, doi: 10.1111/j.1442-2042.2012.03135.xGoogle Scholar
  50. 50.
    Lee JD, Lee MH (2011) Increased expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor associated with glomerulation formation in patients with interstitial cystitis. Urology 78(4):971.11–15PubMedGoogle Scholar
  51. 51.
    Li GZ, Zhang N, Du P et al (2010) Risk factors for interstitial cystitis/painful bladder syndrome in patients with lower urinary tract symptoms: a Chinese multi-center study. Chin Med J (Engl) 123(20):2842–2846Google Scholar
  52. 52.
    Liu HT, Shie JH, Chen SH et al (2012) Differences in mast cell infiltration, E-cadherin, and zonula occludens-1 expression between patients with overactive bladder and interstitial cystitis/bladder pain syndrome. Urology 80(1):225PubMedCrossRefGoogle Scholar
  53. 53.
    Logadottir Y, Fall M, Kabjörn-Gustafsson C, Peeker R (2012) Clinical characteristics differ considerably between phenotypes of bladder pain syndrome/interstitial cystitis. Scand J Urol Nephr 46(5):365–370CrossRefGoogle Scholar
  54. 54.
    Logadottir Y, Hallsberg L, Fall M et al (2012) Bladder pain syndrome/interstitial cystitis ESSIC type 3C: high expression of inducible nitric oxide synthase in inflammatory cells. Scand J Urol Nephr 47(1):52–56Google Scholar
  55. 55.
    Mayson BE, Teichman JM (2009) The relationship between sexual abuse and interstitial cystitis/painful bladder syndrome. Curr Urol Rep 10(6):441–447PubMedCrossRefGoogle Scholar
  56. 56.
    Marinkovic SP, Gillen LM, Marinkovic CM (2011) Minimum 6-year outcomes for interstitial cystitis treated with sacral neuromodulation. Int Urogynecol J 22(4):407–412PubMedCrossRefGoogle Scholar
  57. 57.
    Merwe JP van de, Nordling J, Bouchelouche P et al (2008) Diagnostic criteria, classification, and nomenclature for painfull bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol 53:60–67PubMedCrossRefGoogle Scholar
  58. 58.
    National Institute of Diabetes and Digestive and Kidney Diseases (2011) Interstitial cystitis/painful bladder syndrome. NIH publication no. 11–3220Google Scholar
  59. 59.
    Neuhaus J, Schulte-Baukloh H, Stolzenburg JU et al (2011) Individual receptor profiling as a novel tool to support diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC). World J Urol 30(5):693–700PubMedCrossRefGoogle Scholar
  60. 60.
    Nickel JC (2004) Interstitial cystitis: a chronic pelvic pain syndrome. Med Clin North Am 88(2):467–481PubMedCrossRefGoogle Scholar
  61. 61.
    Nickel JC, Tripp D (2007) Sexual function is a determinant of poor quality of life for women with treatment refractory interstitial cystitis. J Urol 177(5):1832–1836PubMedCrossRefGoogle Scholar
  62. 62.
    Nickel JC, Shoskes DA, Irvine-Bird K (2010) Prevalence and impact of bacteriuria and/or urinary tract infection in interstitial cystitis/painful bladder syndrome. Urology 76(4):799–803PubMedCrossRefGoogle Scholar
  63. 63.
    Nickel JC, Tripp DA, Pontari M et al (2010) Interstitial cystitis/painful bladder syndrome and associated medical conditions with an emphasis on irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome. J Urol 184(4):1358–1363PubMedCrossRefGoogle Scholar
  64. 64.
    Nickel JC, Tripp DA, Pontari M et al (2011) Childhood sexual trauma in women with interstitial cystitis/bladder pain syndrome: a case control study. Can Urol Assoc J 5(6):410–415PubMedCrossRefGoogle Scholar
  65. 65.
    Nickel JC, Jain P, Shore N et al (2012) Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Transl Med 4(143):143CrossRefGoogle Scholar
  66. 66.
    Nickel JC, Hanno P, Kumar K, Thomas H (2012) Second multicenter, randomized, double-blind, parallel-group evaluation of effectiveness and safety of intravesical sodium chondroitin sulfate compared with inactive vehicle control in subjects with interstitial cystitis/bladder pain syndrome. Urology 79(6):1220–1224PubMedCrossRefGoogle Scholar
  67. 67.
    Nordling J, Fall M, Hanno P (2011) Global concepts of bladder pain syndrome (interstitial cystitis). World J Urol 30(4):457–464PubMedCrossRefGoogle Scholar
  68. 68.
    Nordling J, Fall M, Hanno P (2012) Global concepts of bladder pain syndrome (interstitial cystitis). World J Urol 30(4):457–464PubMedCrossRefGoogle Scholar
  69. 69.
    Panzera AK, Reishtein J, Shewokis P (2011) Sleep disruption and interstitial cystitis symptoms in women. Urol Nurs 31(3):159–165PubMedGoogle Scholar
  70. 70.
    Parsons CL (2010) The role of a leaky epithelium and potassium in the generation of bladder symptoms in interstitial cystitis/overactive bladder, urethral syndrome, prostatitis and gynaecological chronic pelvic pain. BJU int 107(3):370–375PubMedCrossRefGoogle Scholar
  71. 71.
    Parsons CL, Zupkas P, Proctor J et al (2012) Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis. J Sex Med 9(1):207–212PubMedCrossRefGoogle Scholar
  72. 72.
    Peters KM, Carrico DJ, Diokno AC (2008) Characterization of a clinical cohort of 87 women with interstitial cystitis/painful bladder syndrome. Urology 71(4):634–640PubMedCrossRefGoogle Scholar
  73. 73.
    Peters KM, Killinger KA, Mounayer MH, Boura JA (2011) Are ulcerative and nonulcerative interstitial cystitis/painful bladder syndrome 2 distinct diseases? A study of coexisting conditions. Urology 78(2):301–308PubMedCrossRefGoogle Scholar
  74. 74.
    Pfaff H, Neugebauer EA, Glaeske G, Schrappe M (Hrsg) (2011) Lehrbuch Versorgungsforschung. Schattauer, StuttgartGoogle Scholar
  75. 75.
    Pontari MA, Ruggieri MR (2008) Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol 179(Suppl 5):61–67CrossRefGoogle Scholar
  76. 76.
    Porru D, Leva F, Parmigiani A et al (2012) Impact of intravesical hyaluronic acid and chondroitin sulfate on bladder pain syndrome/interstitial cystitis. Int Urogynecol J 23(9):1193–1199PubMedCrossRefGoogle Scholar
  77. 77.
    Propert KJ, Payne C, Kusek JW et al (2002) Pitfalls in the design of clinical trials for interstitial cystitis. Urology 60(5):742–748PubMedCrossRefGoogle Scholar
  78. 78.
    Quillin RB, Erickson DR (2012) Practical use of the New American Urological Association Interstitial Cystitis guidelines. Curr Urol Rep 13(5):394–401PubMedCrossRefGoogle Scholar
  79. 79.
    Quillin RB, Erickson DR (2012) Management of interstitial cystitis/bladder pain syndrome: a urology perspective. Urol Clin North Am 39(3):389–396PubMedCrossRefGoogle Scholar
  80. 80.
    Rais-Bahrami S, Friedlander JI, Herati AS et al (2012) Symptom profile variability of interstitial cystitis/painful bladder syndrome by age. BJU Int 109(9):1356–1359PubMedCrossRefGoogle Scholar
  81. 81.
    Röllig C (2011) Grenzen der Versorgungsforschung. Urologe 50:697–701PubMedCrossRefGoogle Scholar
  82. 82.
    Rothrock NE (2001) Stress and symptoms in patients with interstitial cystitis: a life stress model. Urology 57(3):422–427PubMedCrossRefGoogle Scholar
  83. 83.
    Rovner ES, Kim ED (2011) Interstitial cystitis. http://emedicine.medscape.com/article/441831/overviewGoogle Scholar
  84. 84.
    Sant GR (1997) Interstitial cystitis. Curr Opin Obstet Gynecol 9(5):332–336PubMedCrossRefGoogle Scholar
  85. 85.
    Schwalenberg T, Stolzenburg JU, Ho TP et al (2012) Enhanced urothelial expression of human chorionic gonadotropin beta (hCGbeta) in bladder pain syndrome/interstitial cystitis (BPS/IC). World J Urol 30(3):411–417PubMedCrossRefGoogle Scholar
  86. 86.
    Shie JH, Kuo HC (2011) Higher levels of cell apoptosis and abnormal E-cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis/painful bladder syndrome. BJU Int 108(2):136–141CrossRefGoogle Scholar
  87. 87.
    Shorter B, Lesser M, Moldwin RM, Kushner L (2007) Effect of comestibles on symptoms of interstitial cystitis. J Urol 178(1):145–152PubMedCrossRefGoogle Scholar
  88. 88.
    Stav K, Berashvili I, Lindner A, Leibovici D (2012) Predictors of response to intravesical dimethyl-sulfoxide cocktail in patients with interstitial cystitis. Urology 80(1):61–65PubMedCrossRefGoogle Scholar
  89. 89.
    Sugihara T, Yasunage H, Horiguchi H et al (2012) Admissions related to interstitial cystitits in Japan: an estimation based on the Japanes diagnosis procedure combination database. Int J Urol 19(1):86–89PubMedCrossRefGoogle Scholar
  90. 90.
    Tunitsky E, Barber MD, Jeppson PC et al (2012) Bladder pain syndrome/interstitial cystitis in twin sisters. J Urol 187(1):148–152PubMedGoogle Scholar
  91. 91.
    Tyagi P, Killinger K, Tyagi V et al (2012) Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitis. J Urol 187(6):2243–2248PubMedCrossRefGoogle Scholar
  92. 92.
    Vela Navarrete R, Enguita G (2012) Interstitial cystitis: one hundred years of mysteries and frustration. Timely Top Med Uro Int 14:7–90005Google Scholar
  93. 93.
    Walid MS, Heaton RL (2011) Interstitial cystitis and endometriosis in a 12-year-old girl. Arch Gynecol Obstet 283(1):115–117PubMedCrossRefGoogle Scholar
  94. 94.
    Warren JW, Brown J, Tracy JK et al (2008) Evidence-based criteria for pain of interstitial cystitis/painful bladder syndrome in women. Urology 71(3):444–448PubMedCrossRefGoogle Scholar
  95. 95.
    Warren JW, Brown V, Jacobs S et al (2008) Urinary tract infection and inflammation at onset of interstitial cystitis/painful bladder syndrome. Urology 71(6):1085–1090PubMedCrossRefGoogle Scholar
  96. 96.
    Warren JW, Diggs C, Horne L, Greenberg P (2010) Interstitial cystitis/painful bladder syndrome: what do patients mean by „perceived“ bladder pain? Urology 77(2):309–312PubMedCrossRefGoogle Scholar
  97. 97.
    Warren JW, Greenberg P, Diggs C et al (2010) A prospective early history of incident interstitial cystitis/painful bladder syndrome. J Urol 184(6):2333–2338PubMedCrossRefGoogle Scholar
  98. 98.
    Warren JW, Wesselmann U, Morozov V, Langenberg PW (2011) Numbers and types of nonbladder syndromes as risk factors for interstitial cystitis/painfull bladder syndrome. Urology 77(2):313–319PubMedCrossRefGoogle Scholar
  99. 99.
    Warren JW, Clauw DJ, Langenberg P (2012) Prognostic factors for recent-onset interstitial cystitis/painful bladder syndrome. BJU Int 21(11):1139–1143Google Scholar
  100. 100.
    Watkins KE, Eberhart N, Hilton L et al (2011) Depressive disorders and panic attacks in women with bladder pain syndrome/interstitial cystitis: a population-based sample. Gen Hosp Psychiatry 33(2):143–149PubMedCrossRefGoogle Scholar
  101. 101.
    Weißbach L (2011) Standortverstimmung. Urologe 50:671PubMedCrossRefGoogle Scholar
  102. 102.
    Wu EQ, Birnbaum H, Mareva M et al (2006) Interstitial cystitis – cost, treatment and co-morbidities in an employed population. Pharmacoeconomics 24(1):55–65PubMedCrossRefGoogle Scholar
  103. 103.
    Wyllie MG (2010) Interstitial Cystitis: a negative ongoing situation? BJU int 106:1401–1402PubMedCrossRefGoogle Scholar
  104. 104.
    Yoost JL, Hertweck SP, Loveless M (2012) Diagnosis and treatment of interstitial cystitis in adolescents. J Pediatr Adolesc Gynecol 25(3):162–171PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • D. Jocham
    • 1
  • G. Froehlich
    • 2
  • F. Sandig
    • 3
  • A. Ziegler
    • 3
  1. 1.Urologische Klinik und PoliklinikUniversität zu Lübeck, Universitätsklinikum Schleswig-Holstein, Campus LübeckLübeckDeutschland
  2. 2.Toscolano MadernoItalien
  3. 3.Institut für Medizinische Biometrie und StatistikUniversität zu Lübeck, Universitätsklinikum Schleswig-Holstein, Campus LübeckLübeckDeutschland

Personalised recommendations